View in EDS HTML Full Text PDF Full Text

Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.

Saved in:
Bibliographic Details
Title: Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Authors: Dosne AG; Janssen Research and Development, Beerse, Belgium., Valade E; Janssen Research and Development, Beerse, Belgium., Goeyvaerts N; Janssen Research and Development, Beerse, Belgium., De Porre P; Janssen Research and Development, Beerse, Belgium., Avadhani A; Janssen Research and Development, Spring House, PA, USA., O'Hagan A; Janssen Research and Development, Spring House, PA, USA., Li LY; Janssen Research and Development, Spring House, PA, USA., Ouellet D; Janssen Research and Development, Spring House, PA, USA., Perez Ruixo JJ; Janssen Research and Development, Beerse, Belgium. jjperezr@ITS.JNJ.com.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Feb; Vol. 89 (2), pp. 151-164. Date of Electronic Publication: 2022 Jan 03.
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34977972
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dosne+AG%22">Dosne AG</searchLink>; Janssen Research and Development, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Valade+E%22">Valade E</searchLink>; Janssen Research and Development, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Goeyvaerts+N%22">Goeyvaerts N</searchLink>; Janssen Research and Development, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22De+Porre+P%22">De Porre P</searchLink>; Janssen Research and Development, Beerse, Belgium.<br /><searchLink fieldCode="AU" term="%22Avadhani+A%22">Avadhani A</searchLink>; Janssen Research and Development, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22O'Hagan+A%22">O'Hagan A</searchLink>; Janssen Research and Development, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Li+LY%22">Li LY</searchLink>; Janssen Research and Development, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Ouellet+D%22">Ouellet D</searchLink>; Janssen Research and Development, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Perez+Ruixo+JJ%22">Perez Ruixo JJ</searchLink>; Janssen Research and Development, Beerse, Belgium. jjperezr@ITS.JNJ.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227806519%22">Cancer chemotherapy and pharmacology</searchLink> [Cancer Chemother Pharmacol] 2022 Feb; Vol. 89 (2), pp. 151-164. <i>Date of Electronic Publication: </i>2022 Jan 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>7806519 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0843 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203445704%22">03445704 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Chemother Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34977972
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00280-021-04381-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 151
    Titles:
      – TitleFull: Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dosne AG
      – PersonEntity:
          Name:
            NameFull: Valade E
      – PersonEntity:
          Name:
            NameFull: Goeyvaerts N
      – PersonEntity:
          Name:
            NameFull: De Porre P
      – PersonEntity:
          Name:
            NameFull: Avadhani A
      – PersonEntity:
          Name:
            NameFull: O'Hagan A
      – PersonEntity:
          Name:
            NameFull: Li LY
      – PersonEntity:
          Name:
            NameFull: Ouellet D
      – PersonEntity:
          Name:
            NameFull: Perez Ruixo JJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2022 Feb
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0843
          Numbering:
            – Type: volume
              Value: 89
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Cancer chemotherapy and pharmacology
              Type: main
ResultId 1